Orchard enters agreement with Beneluxa enabling reimbused access to Libmeldy

Orchard Therapeutics announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy, Beneluxa, enabling reimbursed access to Libmeldy, a hematopoietic stem cell, HSC, gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy, MLD. The agreement covers several member countries, including Belgium, The Netherlands, and Ireland. It follows similar arrangements made with reimbursement authorities in the United Kingdom, Italy, Germany, Sweden, Iceland, Finland and Norway, and is a key component of the company’s geographic expansion plans. “Following its approval, health technology assessment authorities across Europe have continued to recognize the impact of Libmeldy commensurate with its clinical, economic and societal value,” said Robin Kenselaar, senior vice president, EMEA at Orchard Therapeutics. “We are pleased to have reached an agreement with the Beneluxa consortium that enables sustainable access to treatment. The agreement came after the acceptance of additional long-term data and marks a reversal of the outcome from earlier negotiations with the consortium which ended without reaching an arrangement. We remain committed to broadening access to this important therapy in new geographies for the benefit of eligible patients and their families.”